Med · Oct 2026
Read original source →Endovascular treatment for ischemic stroke due to distal medium vessel occlusions: A nationwide multicenter registry
Outside a trial, fourfold symptomatic haemorrhage risk against a gain of about four percentage points in mRS 0–1 is the trade-off to weigh.
Highlights
- EvidenceRetrospective cohort
- What to watch: SAIL-MEVO (NCT07843797), a randomised trial of thrombectomy versus best medical therapy, has an estimated primary completion of January 2029.
Index entry — verify clinical detail against the primary source.
Related conditions
For learning and professional reference; not a patient-specific recommendation. How we prepare content.